Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis
Status:
Terminated
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
This was a multicenter, randomized, open-label, parallel-group, active-controlled study.
Prior to randomization, participants were to have been treated with glatiramer acetate or
interferon β-1a (44 μg). Participants were to be randomized to receive natalizumab,
interferon β-1a 44 μg, or glatiramer acetate.